---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-050881"
form_type: "8-K"
ticker: null
cik: "0000924717"
company_name: "SURMODICS INC"
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T03:47:27.769399+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Surmodics Q2 revenue $32M (+18% YoY), GAAP net income $0.2M; raises FY2024 guidance; launches two thrombectomy devices

## Summary
- Total revenue $32.0M, up 18% YoY; GAAP net income $0.2M vs loss of $7.7M in prior-year period.
- Medical Device product sales up 40% to $11.1M, driven by SurVeil DCB commercial shipments and Pounce sales.
- Adjusted EBITDA $4.8M, improving from $(1.5M) in Q2 fiscal 2023.
- FY2024 guidance raised: revenue now $122-$124M; GAAP diluted loss per share $(0.90)-$(0.70) vs prior $(1.40)-$(1.10).
- Commercial launch of Pounce Venous and Pounce LP thrombectomy systems; cash and investments $40.9M.

## SEC filing metadata
- accession: 0000950170-24-050881
- form_type: 8-K
- cik: 0000924717
- company_name: SURMODICS INC
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/924717/000095017024050881/0000950170-24-050881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/924717/000095017024050881/srdx-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-050881
- JSON: https://secwatch.observer/filing/0000950170-24-050881.json
- Plain text: https://secwatch.observer/filing/0000950170-24-050881.txt

## Key facts
- Earnings Releases
  SURMODICS INC reported second quarter ended March 31, 2024 results: revenue $32.0 million, net income $0.2 million. Guidance raised.
  - Period: second quarter ended March 31, 2024
  - Revenue: $32.0 million
  - Net income: $0.2 million
  - Guidance: raised
  - Result: reported results
  source text: today reported financial results for its second quarter ended March 31, 2024, and updated financial guidance for its fiscal year ending September 30, 2024. Second Quarter Fiscal 2024 Financial Summary • Total Revenue of $32.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/924717/000095017024050881/0000950170-24-050881-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.